Poster Abstract Session:
163. Mycology - There's a Fungus Among Us: Treatment
Friday, October 28, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

.

Tracks: Adult ID

Presentations:
National Estimates of Antifungal Use among Inpatients Based on Administrative Data─United States, 2006–2012.
Snigdha Vallabhaneni, MD, MPH ; James Baggs, PhD ; Shawn Lockhart, PhD ; John Jernigan, MD, MS ; Brendan Jackson, MD, MPH
Effectiveness and Safety of New Posaconazole Formulations in Patients With Hematologic Malignancy Receiving Antifungal Prophylaxis
Samuel L. Aitken, PharmD ; Sang Taek Heo, M.D. PhD. ; Frank P. Tverdek, PharmD ; Bruno P. Granwehr, MD, M.S. ; Dimitrios P. Kontoyiannis, MD, ScD, FIDSA
Efficacy and Safety of Chronic Suppressive Azole Therapy for Endemic Fungal Infections in Solid Organ Transplant Recipients
Sonya Trinh, MD, MPH ; Michael Angarone, DO ; Sudhir Penugonda, MD MPH ; Ignacio Echenique, MD
Posters
  • Trinh_EFI.pdf (966.0 kB)
  • Activity of Isavuconazole and Comparator Mould-Active Triazoles Tested against Contemporary Invasive Mould Isolates
    Michael Pfaller, MD, FIDSA ; Shawn a. Messer, MS-MT ; Rachel D. Dietrich, BA ; Paul R. Rhomberg, BS ; Mariana Castanheira, PhD
    How common is Subsequent Central Nervous System (CNS) Toxicity in Patients (pts) with Hematologic Malignancy (HM) and Supra-therapeutic Voriconazole (VRC) Serum Levels?
    Sang Taek Heo, M.D. PhD. ; Samuel L. Aitken, PharmD ; Frank P. Tverdek, PharmD ; Dimitrios P. Kontoyiannis, MD, ScD, FIDSA
    Retinoic Acid is not Involved in Fluconazole Induced Alopecia: evaluation in a human cohort and rat model
    George R. Thompson, MD ; Charles Krois, PhD ; Verena Affolter, DVM ; Angela Everett, DVM ; Katarina Varjonen, DVM ; Victoria Sharon, MD ; Anil Singapuri, MS ; Michael Dennis, BS ; Dawn Fedor, PhD ; Nathan P. Wiederhold, PharmD ; Angie Gelli, PhD ; Joseph Napoli, PhD ; Stephen White, DVM
    Hepatic Safety of Isavuconazole Compared with Voriconazole in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Complicated by Invasive Mold Disease – A Post-Hoc Analysis from the SECURE Study
    Werner J. Heinz, MD ; Oliver Cornely, MD, FACP, FIDSA, FAAM ; Dominik Selleslag, MD ; Galia Rahav, MD ; Michael Giladi, MD ; Mickael Aoun, MD ; Raoul Herbrecht, MD ; Andrew J. Ullmann, MD ; Nkechi Azie, MD ; Laura Kovanda, BA ; Achim Kaufhold, MD ; Marc Engelhardt, MD ; Johan Maertens, MD, PhD
    Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates
    Michael Pfaller, MD, FIDSA ; Shawn a. Messer, MS-MT ; Paul R. Rhomberg, BS ; Sarah E. Costello, BS ; Mariana Castanheira, PhD
    Posters
  • IDWeek16 CD101 1625-final.pdf (316.2 kB)
  • Tablet OR Suspension Of posacoanazole study(TORSO study)
    Harpal Dhillon, PhD MRPharmS ; Darren Cooper, BPharm MRPharmS ; Helen Tate, Statistician ; Jude Robinson, Medical Affairs Research Manager ; Harpal Lamba, BSc MBA MFPM FRCP(UK)
    Serum Concentrations of Posaconazole (PCZ) with Delayed-Release Tablets (DRT) in High-risk Patients
    Alan Chin, PharmD ; Steven a. Pergam, MD ; David N Fredricks, MD ; Rupali Jain, Pharm.D.
    Use of posaconazole intravenous solution and delayed-release oral tablets at a tertiary medical center
    Michelle Pasciolla, PharmD ; Christine J. Kubin, PharmD BCPS (AQ-ID) ; Brian Nelson, PharmD
    In vivo biomarker analysis of intranasally dosed PC945, a novel antifungal agent, in Aspergillus fumigatus infection in immunocompromised mice
    Kazuhiro Ito, PhD ; Yasuo Kizawa, PhD ; Genki Kimura, PhD ; Takahiro Nakaoki, BSc ; Lindsey Cass, PhD ; Duncan Hunt, - ; Toby M. HUNT, BTECH ; Trevor L. HUNT, - ; Pete Strong, PhD ; Garth Rapeport, MD
    Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis
    Guillaume Butler-Laporte, MDCM ; Charles Poirier, MD ; Pasquale Ferraro, MD ; Marie-Claude Langevin, PharmD ; Claude Lemieux, MD ; Yves Theoret, MD ; Me-Linh Luong, MD
    Posters
  • IDWeek_Vori.pdf (521.7 kB)
  • A marginal structural approach to measuring the comparative effectiveness of echinocandins vs. fluconazole therapy for the treatment of adult candidemia (MSG-12)
    Laura Anatale-Tardiff, MPH ; Kelly Getz, PhD, MPH ; Rui Xiao, PhD ; John Baddley, MD ; Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA ; Peter Pappas, MD ; Theoklis Zaoutis, MD, MSCE ; Brian Fisher, DO, MPH, MSCE
    Blockade of Ccr1 is an immune-based approach that protects mice from systemic candidiasis of hematogenous origin
    Michail Lionakis, MD, ScD ; Nathaniel Albert, BS ; Muthulekha Swamydas, PhD ; Pius Loetscher, PhD ; Dimitrios P. Kontoyiannis, MD, ScD, FIDSA
    VT-1129 and VT-1161 have in vitro activity against Candida isolates from patients with chronic mucocutaneous candidiasis
    Jigar V Desai, PhD ; Timothy J Break, PhD ; Mukil Natarajan, MD ; Christina Henderson, BS ; Adrian M Zelazny, PhD ; William J Hoekstra, PhD ; Robert J Schotzinger, MD/PhD ; Edward P Garvey, PhD ; Michail S Lionakis, MD, ScD
    Outcomes Comparing Initial Fluconazole to Micafungin in ICU Patients with Candidemia
    Deborah Theodore, MD ; Amrita Singh, PharmD ; Angela Loo, PharmD BCPS (AQ-ID) ; Gregory Eschenauer, PharmD ; Ryan K. Shields, PharmD ; Christine J. Kubin, PharmD BCPS (AQ-ID) ; Magdalena Sobieszczyk, MD, MPH
    Posters
  • IDWeek2016_Candida_ICU.pdf (2.5 MB)
  • Echinocandin resistance in Candida glabrata bloodstream infection 2009-2015 at a single institution
    Todd Mccarty, MD ; Joanna Zurko, MD ; Shawn Lockhart, PhD ; Cau Pham, PhD ; Jennifer Whiddon, BS ; Stephen Moser, PhD ; Peter Pappas, MD
    Investigational CYP51 Inhibitors VT-1161 and VT-1129 Show Strong Activity In Vitro Against Candida krusei
    Barbara D. Alexander, MD, MHS, FIDSA ; Wiley a. Schell, MS ; Alexander Jones, B.S. ; William J Hoekstra, PhD ; Robert J Schotzinger, MD/PhD ; Edward P Garvey, PhD
    Retrospective Study of Outcomes Comparing Initial Treatment with Fluconazole or Micafungin in Immunosuppressed Patients with Candidemia
    Amrita Singh, PharmD ; Deborah Theodore, MD ; Angela Loo, PharmD BCPS (AQ-ID) ; Ryan K. Shields, PharmD ; Gregory Eschenauer, PharmD ; Magdalena Sobieszczyk, MD, MPH ; Christine J. Kubin, PharmD BCPS (AQ-ID)
    Risk Factors for Micafungin non-susceptible Candida isolates
    Natasha Pettit, PharmD ; Zhe Han, PharmD ; Jennifer Pisano, MD ; Angella Charnot-Katsikas, MD
    A Novel Therapeutic Approach for Cryptococcal Meningitis
    Drew Cutshaw, B.S. ; Alykhan Premji, B.S. ; Promila Pagadala, Ph.D. ; Charles Giamberardino, M.R. ; Aaron Mccabe, Ph.D. ; Shivanand P. Lad, M.D., Ph.D. ; John R Perfect, M.D., FIDSA
    Posters
  • ID Week POSTER D4B.pdf (1.3 MB)
  • Relationship between intracranial hypertension and antifungal agent levels in the CSF of patients with cryptococcal meningitis
    Fernanda Wirth, M.S ; Carmen Pilla, M.S ; Valerio Aquino, PhD ; Gustavo Wissmann, PhD, MD ; Luciano Goldani, PhD, MD
    Antifungal susceptibility profiles of Onychomycosis caused by different species of Fusarium
    Priscila Dallé Da Rosa, MSC ; Daiane Heidrich, MSC ; Caroline Corrêa, MS ; Maria Lúcia Scroferneker, PhD ; Gerson Vettorato, MD ; Alexandre Fuentefria, PhD ; Luciano Goldani, PhD, MD
    Comparison of Posaconazole and Itraconazole for treatment of Histoplasmosis
    Krishna Bobbili, MD ; Sami Akram, MD ; Vidya Sundareshan, MD, MPH ; Vidhya Prakash, MD ; Isha Tyagi, MD ; Sana Waqar, MD ; Scott Bergman, PharmD ; Janak Koirala, MD, FIDSA

    CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.